Key result
Impella 5.5 was associated with higher survival through explant compared to Impella 5.0 in AMICS (70.5% vs 56.8%), cardiomyopathy (88.1% vs 76.9%), and PCCS (76.1% vs 55.7%).
Why the study?
A redesigned surgically implanted heart pump incorporates several design changes from the prior generation, but no published comparative data demonstrated whether these changes translate to improved clinical outcomes.
Does the Impella 5.5 improve survival through explant compared to the Impella 5.0 in patients with cardiogenic shock or cardiomyopathy?
Cohort (n=1,238)
Yes
Does the Impella 5.5 improve survival through explant compared to the Impella 5.0 in patients with cardiogenic shock or cardiomyopathy?
No takes yet. Share an insight, caveat, or question.
Impella 5.5 may offer better outcomes than 5.0 in cardiogenic shock; leaves open whether redesign confers causal benefit pending randomized data.
Ramzy et al. (2023) conducted a cohort in Cardiogenic shock and heart failure (AMICS, cardiomyopathy, or PCCS) (n=1,238). Impella 5.5 vs. Impella 5.0 was evaluated on Survival through explant (successfully weaned or bridged to heart replacement therapy). Impella 5.5 was associated with higher survival through explant compared to Impella 5.0 in AMICS (70.5% vs 56.8%), cardiomyopathy (88.1% vs 76.9%), and PCCS (76.1% vs 55.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: